Illumina (NASDAQ:ILMN) Given New $130.00 Price Target at JPMorgan Chase & Co.

Illumina (NASDAQ:ILMN) had its price objective hoisted by analysts at JPMorgan Chase & Co. from $105.00 to $130.00 in a report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s price target points to a potential downside of 3.44% from the company’s current price.

ILMN has been the subject of a number of other reports. Cowen restated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd. TD Cowen boosted their price target on Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research report on Friday, October 31st. Royal Bank Of Canada set a $124.00 price target on Illumina in a research note on Tuesday, September 2nd. Finally, Barclays restated an “underweight” rating and issued a $110.00 price target on shares of Illumina in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $117.19.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded down $0.24 during trading on Monday, reaching $134.64. The stock had a trading volume of 903,186 shares, compared to its average volume of 2,122,438. The stock has a fifty day simple moving average of $114.71 and a two-hundred day simple moving average of $102.88. The company has a quick ratio of 1.12, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Illumina has a 52 week low of $68.70 and a 52 week high of $153.06. The firm has a market capitalization of $20.57 billion, a price-to-earnings ratio of 30.19, a P/E/G ratio of 2.41 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, analysts anticipate that Illumina will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.17% of the company’s stock.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. Rise Advisors LLC increased its stake in Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 224 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares in the last quarter. Quent Capital LLC bought a new stake in Illumina in the 3rd quarter worth approximately $29,000. Quarry LP purchased a new stake in Illumina in the third quarter worth approximately $32,000. Finally, Aster Capital Management DIFC Ltd bought a new position in Illumina during the third quarter valued at approximately $33,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.